FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894467402> ?p ?o ?g. }

• W2894467402 endingPage "34258" @default.
• W2894467402 startingPage "34240" @default.
• W2894467402 abstract "Internal tandem duplication (ITD) in Fms-like tyrosine kinase 3 (FLT3) is frequently observed in acute myeloid leukemia (AML). Quizartinib, gilteritinib, and midostaurin are inhibitors against FLT3-ITD that have good efficacy for FLT3-ITD-positive AML patients. Long-term administration leads to drug resistance through acquired tyrosine kinase domain (TKD) mutations in FLT3-ITD, such as N676K, F691L, D835V, and Y842C. Here, our screen to detect inhibitors capable of overcoming resistance to FLT3 inhibitors identified heat shock protein (HSP) 90 inhibitors as potential candidates. Although Ba/F3 cells expressing FLT3-ITD with TKD mutations (Ba/F3-ITD+N676K, Ba/F3-ITD+F691L, Ba/F3-ITD+D835V, and Ba/F3-ITD+Y842C) showed various resistance patterns to FLT3 inhibitors compared with Ba/F3-ITD cells that express FLT3-ITD lacking TKD mutations, they were more sensitive to HSP90 inhibitors than Ba/F3 cells. Notably, the Ba/F3-ITD+D835V cells were the most sensitive to HSP90 inhibitors. Treatment with HSP90 inhibitors downregulated FLT3 and its downstream signaling and induced G1 arrest followed by apoptosis in Ba/F3-ITD+N676K, Ba/F3-ITD+F691L, Ba/F3-ITD+Y842C, and especially Ba/F3-ITD+D835V cells at lower concentrations compared with Ba/F3-ITD cells. The downregulation of FLT3-ITD+D835V was caused by rapid proteolysis in autophagy. Similar results were also observed in the quizartinib-resistant MV4-11 cells, QR1 and QR2, which were established by culturing cells in the presence of quizartinib and harbored FLT3-ITD+D835H and FLT3-ITD+D835V, respectively, in a single allele. Interestingly, the efficacies of HSP90 inhibitors in QR cells are reversely correlated with that of quizartib, but not to gilteritinib and midostaurin. Collectively, HSP90 inhibitors are good candidates to overcome drug resistance in AML with various FLT3-ITD TKD mutations." @default.
• W2894467402 created "2018-10-05" @default.
• W2894467402 creator A5016795795 @default.
• W2894467402 creator A5050674818 @default.
• W2894467402 creator A5087693700 @default.
• W2894467402 date "2018-09-28" @default.
• W2894467402 modified "2023-10-01" @default.
• W2894467402 title "Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia" @default.
• W2894467402 cites W1504864970 @default.
• W2894467402 cites W1567091232 @default.
• W2894467402 cites W1567602112 @default.
• W2894467402 cites W1965283174 @default.
• W2894467402 cites W1969075054 @default.
• W2894467402 cites W1984209370 @default.
• W2894467402 cites W1997476230 @default.
• W2894467402 cites W1999614615 @default.
• W2894467402 cites W2002910631 @default.
• W2894467402 cites W2003225492 @default.
• W2894467402 cites W2005691176 @default.
• W2894467402 cites W2015616444 @default.
• W2894467402 cites W2017107901 @default.
• W2894467402 cites W2021425093 @default.
• W2894467402 cites W2027007307 @default.
• W2894467402 cites W2035292254 @default.
• W2894467402 cites W2045587009 @default.
• W2894467402 cites W2080352180 @default.
• W2894467402 cites W2082117339 @default.
• W2894467402 cites W2090453777 @default.
• W2894467402 cites W2092204388 @default.
• W2894467402 cites W2113230030 @default.
• W2894467402 cites W2133422931 @default.
• W2894467402 cites W2136245759 @default.
• W2894467402 cites W2144830414 @default.
• W2894467402 cites W2152333235 @default.
• W2894467402 cites W2154742235 @default.
• W2894467402 cites W2157228274 @default.
• W2894467402 cites W2168342352 @default.
• W2894467402 cites W2337256135 @default.
• W2894467402 cites W2544147855 @default.
• W2894467402 cites W2552548149 @default.
• W2894467402 cites W2558945204 @default.
• W2894467402 cites W2611389607 @default.
• W2894467402 cites W2620653306 @default.
• W2894467402 cites W2654449699 @default.
• W2894467402 cites W2743873151 @default.
• W2894467402 cites W2748922433 @default.
• W2894467402 cites W2750218280 @default.
• W2894467402 cites W2761881371 @default.
• W2894467402 cites W2767130235 @default.
• W2894467402 cites W2769885694 @default.
• W2894467402 cites W560362396 @default.
• W2894467402 doi "https://doi.org/10.18632/oncotarget.26045" @default.
• W2894467402 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6188142" @default.
• W2894467402 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30344940" @default.
• W2894467402 hasPublicationYear "2018" @default.
• W2894467402 type Work @default.
• W2894467402 sameAs 2894467402 @default.
• W2894467402 citedByCount "18" @default.
• W2894467402 countsByYear W28944674022019 @default.
• W2894467402 countsByYear W28944674022020 @default.
• W2894467402 countsByYear W28944674022021 @default.
• W2894467402 countsByYear W28944674022022 @default.
• W2894467402 countsByYear W28944674022023 @default.
• W2894467402 crossrefType "journal-article" @default.
• W2894467402 hasAuthorship W2894467402A5016795795 @default.
• W2894467402 hasAuthorship W2894467402A5050674818 @default.
• W2894467402 hasAuthorship W2894467402A5087693700 @default.
• W2894467402 hasBestOaLocation W28944674021 @default.
• W2894467402 hasConcept C104317684 @default.
• W2894467402 hasConcept C205260736 @default.
• W2894467402 hasConcept C2775932338 @default.
• W2894467402 hasConcept C2776481607 @default.
• W2894467402 hasConcept C2777560012 @default.
• W2894467402 hasConcept C2778729363 @default.
• W2894467402 hasConcept C2910954276 @default.
• W2894467402 hasConcept C42362537 @default.
• W2894467402 hasConcept C501734568 @default.
• W2894467402 hasConcept C502942594 @default.
• W2894467402 hasConcept C55493867 @default.
• W2894467402 hasConcept C62478195 @default.
• W2894467402 hasConcept C71924100 @default.
• W2894467402 hasConcept C86803240 @default.
• W2894467402 hasConcept C95444343 @default.
• W2894467402 hasConceptScore W2894467402C104317684 @default.
• W2894467402 hasConceptScore W2894467402C205260736 @default.
• W2894467402 hasConceptScore W2894467402C2775932338 @default.
• W2894467402 hasConceptScore W2894467402C2776481607 @default.
• W2894467402 hasConceptScore W2894467402C2777560012 @default.
• W2894467402 hasConceptScore W2894467402C2778729363 @default.
• W2894467402 hasConceptScore W2894467402C2910954276 @default.
• W2894467402 hasConceptScore W2894467402C42362537 @default.
• W2894467402 hasConceptScore W2894467402C501734568 @default.
• W2894467402 hasConceptScore W2894467402C502942594 @default.
• W2894467402 hasConceptScore W2894467402C55493867 @default.
• W2894467402 hasConceptScore W2894467402C62478195 @default.
• W2894467402 hasConceptScore W2894467402C71924100 @default.
• W2894467402 hasConceptScore W2894467402C86803240 @default.
• W2894467402 hasConceptScore W2894467402C95444343 @default.

• next